Ignite Creation Date:
2025-12-25 @ 3:49 AM
Ignite Modification Date:
2026-03-22 @ 7:57 AM
Study NCT ID:
NCT03842202
Status:
COMPLETED
Last Update Posted:
2020-12-24
First Post:
2019-02-13
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity
Sponsor:
Novo Nordisk A/S
Organization:
Study Overview
Official Title:
Effect of Semaglutide 2.4 mg Once-weekly on Gastric Emptying in Subjects With Obesity
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will look at how the emptying of the participant's stomach after a meal is affected by semaglutide (a new medicine) compared to a "dummy" medicine. In addition, the study will also look at the effect of semaglutide on the participant's appetite and energy intake. Participants will either get semaglutide or "dummy" medicine - which treatment any participant gets is decided by chance. Participants will take 1 injection per week. The study medicine is injected with a thin needle in the stomach, thigh or upper arm. The study will last for about 27 weeks (from first treatment to last check-up). Participants will have 8 visits at the clinic with the study doctor.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?: